Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib + R-GemOx in R/R DLBCL
NCT07570017Phase 1Recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rocbrutinib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Lupeng Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
rocbrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07570017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570017.